Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TTN003
MIFTS: 65

Tetanus

Categories: Bone diseases, Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Tetanus

About this section

MalaCards integrated aliases for Tetanus:

Name: Tetanus 12 76 53 59 55 43 3 3 44 15 73
Lockjaw 53 3
Infection Due to Clostridium Tetani 12
Clostridial Tetanus 12

Characteristics:

Orphanet epidemiological data:

59
tetanus
Prevalence: <1/1000000 (France),<1/1000000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Neuronal diseases Bone diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare neurological diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11338
ICD10 33 A35
ICD9CM 35 037
MeSH 44 D013742
NCIt 50 C85185
SNOMED-CT 68 76902006
Orphanet 59 ORPHA3299
UMLS via Orphanet 74 C0039614
ICD10 via Orphanet 34 A33 A34 A35
MESH via Orphanet 45 D013742
UMLS 73 C0039614
Sources

Summaries for Tetanus

About this section
MedlinePlus : 43 Tetanus is a serious illness caused by Clostridium bacteria. The bacteria live in soil, saliva, dust, and manure. The bacteria can enter the body through a deep cut, like those you might get from stepping on a nail, or through a burn. The infection causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw. This makes it impossible to open your mouth or swallow. Tetanus is a medical emergency. You need to get treatment in a hospital. A vaccine can prevent tetanus. It is given as a part of routine childhood immunization. Adults should get a tetanus shot, or booster, every 10 years. If you get a bad cut or burn, see your doctor - you may need a booster. Immediate and proper wound care can prevent tetanus infection.

MalaCards based summary : Tetanus, also known as lockjaw, is related to diphtheria and poliomyelitis, and has symptoms including fever and pruritus. An important gene associated with Tetanus is VAMP7 (Vesicle Associated Membrane Protein 7), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Abatacept and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A primary bacterial infectious disease that results in prolonged contraction of skeletal muscle fibers, has material basis in Clostridium tetani, which produces tetanospasmin, a neurotoxin, which is carried to the brain and spinal cord, where it binds irreversibly to receptors inhibiting neurotransmission. Damaged upper motor neurons cannot control reflex responses to afferent sensory stimuli.

CDC : 3 Tetanus is an infection caused by bacteria called Clostridium tetani. When the bacteria invade the body, they produce a poison (toxin) that causes painful muscle contractions. Another name for tetanus is “lockjaw”. It often causes a person’s neck and jaw muscles to lock, making it hard to open the mouth or swallow. CDC recommends vaccines for infants, children, teens, and adults to prevent tetanus.

Wikipedia : 76 Tetanus, also known as lockjaw, is an infection characterized by muscle spasms. In the most common type,... more...

Sources

Related Diseases for Tetanus

About this section

Diseases related to Tetanus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 370)
# Related Disease Score Top Affiliating Genes
1 diphtheria 32.7 IL13 IL2 IL2RA
2 poliomyelitis 31.1 IFNG IL10 IL4
3 mumps 30.5 IFNG IL2 IL2RA
4 rubella 30.5 CD40LG IL10 IL4
5 lepromatous leprosy 30.3 IFNG IL10 IL2
6 filarial elephantiasis 30.0 IL10 IL4 IL5
7 onchocerciasis 29.9 IL13 IL2 IL4 IL5
8 human immunodeficiency virus infectious disease 29.9 IFNG IL10 IL2
9 myasthenia gravis 29.9 IFNG IL10 IL2 IL4
10 filariasis 29.9 IFNG IL10 IL2 IL5
11 wells syndrome 29.8 IL2 IL2RA IL5
12 psoriasis 29.8 IFNG IL10 IL13 IL2 IL4 LTA
13 pneumonia 29.8 CD40LG IL10 IL13 IL5
14 herpes zoster 29.7 IFNG IL10 IL2
15 milk allergy 29.7 CD79A IL10 IL4 IL5
16 bone inflammation disease 29.7 IFNG IL10 IL2 IL4
17 malaria 29.6 CD40LG IFNG IL10 IL13 IL2 IL4
18 rheumatic disease 29.6 CD40LG IFNG IL10 IL2RA
19 allergic hypersensitivity disease 29.5 IFNG IL10 IL13 IL4 IL5
20 human immunodeficiency virus type 1 29.4 CCR7 IFNG IL10 IL2 LTA
21 asthma 29.3 CD40LG IFNG IL10 IL13 IL2RA IL4
22 multiple sclerosis 29.3 CCR7 IFNG IL10 IL2 IL2RA IL4
23 rheumatoid arthritis 29.3 CD40LG IFNG IL10 IL2 IL2RA IL4
24 inflammatory bowel disease 29.2 IFNG IL10 IL13 IL2 IL4 IL5
25 systemic lupus erythematosus 29.1 CD40LG CD79A IFNG IL10 IL2 IL2RA
26 tetanus neonatorum 12.7
27 crisponi/cold-induced sweating syndrome 1 11.4
28 immunodeficiency 25 11.0
29 specific antibody deficiency 11.0
30 pertussis 11.0
31 haemophilus influenzae 10.7
32 hepatitis 10.6
33 hepatitis b 10.6
34 measles 10.4
35 variola major 10.4 IFNG IL2
36 influenza 10.4
37 b-cell growth factor 10.4 IFNG IL4
38 autoimmune myocarditis 10.3 IFNG IL4
39 autoimmune vasculitis 10.3 IL2 IL4
40 virus associated hemophagocytic syndrome 10.3 IL2 IL4
41 tungiasis 10.3 IL10 IL4
42 streptococcal toxic-shock syndrome 10.3 IL2 LTA
43 recurrent respiratory papillomatosis 10.3 IL13 IL2
44 ascaridiasis 10.3 IL10 IL13
45 large granular lymphocyte leukemia 10.3 IFNG IL2RA
46 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL13 IL5
47 respiratory syncytial virus infectious disease 10.3 IL13 IL5
48 graft-versus-host disease 10.3 IFNG IL10 IL2
49 chagas disease 10.3 IFNG IL10 IL2
50 relapsing-remitting multiple sclerosis 10.3 IFNG IL10 IL4

Graphical network of the top 20 diseases related to Tetanus:



Diseases related to Tetanus
Sources

Symptoms & Phenotypes for Tetanus

About this section

UMLS symptoms related to Tetanus:


fever, pruritus

GenomeRNAi Phenotypes related to Tetanus according to GeneCards Suite gene sharing:

26 (show all 45)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.19 CCR7 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.19 IL13
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.19 IL10
4 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.19 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.19 CCR7 IL10 IL13 VAMP7
6 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.19 IL13
7 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.19 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.19 VAMP7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.19 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.19 VAMP7
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.19 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.19 CCR7
13 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.19 CCR7 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.19 IL13
15 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.19 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.19 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.19 CCR7
18 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.19 VAMP7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.19 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.19 VAMP7
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.19 IL13
22 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.19 VAMP7
23 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.19 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.19 VAMP7
25 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.19 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.19 VAMP7
27 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.19 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.19 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.19 IL10
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.13 IL2RA
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.13 IL2RA
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.13 IL10 NSF
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.13 IL10 IL2RA NSF VAMP7
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.13 IL2RA
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.13 VAMP7
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.13 VAMP7
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.13 IL2RA
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.13 NSF
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.13 IL10 IL2RA
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.13 IL10
41 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.13 IL10
42 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.13 IL10
43 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.13 NSF
44 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CD40LG IL10 IL2 IL2RA LTA STX3
45 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CD27 CD40LG IL10 IL2 IL2RA LTA

MGI Mouse Phenotypes related to Tetanus:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 CCR7 CD40LG CD79A IFNG IL10 IL13
2 hematopoietic system MP:0005397 10.3 CCR7 CD27 CD40LG CD79A IFNG IL10
3 immune system MP:0005387 10.28 CCR7 CD27 CD40LG CD79A IFNG IL10
4 endocrine/exocrine gland MP:0005379 10.22 CCR7 CD40LG IFNG IL10 IL13 IL2
5 mortality/aging MP:0010768 10.13 CD40LG IFNG IL10 IL13 IL2 IL2RA
6 digestive/alimentary MP:0005381 10.1 CCR7 IFNG IL10 IL13 IL2 IL2RA
7 nervous system MP:0003631 10.03 CCR7 CD40LG CD79A IFNG IL10 IL13
8 liver/biliary system MP:0005370 9.97 CD79A IFNG IL10 IL2 IL4 IL5
9 no phenotypic analysis MP:0003012 9.81 CCR7 CD79A IFNG IL10 IL13 IL2
10 respiratory system MP:0005388 9.61 IFNG IL10 IL13 IL2 IL2RA IL4
11 vision/eye MP:0005391 9.28 CCR7 IFNG IL10 IL2 IL2RA IL4
Sources

Drugs & Therapeutics for Tetanus

About this section

Drugs for Tetanus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 331)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4,Phase 2,Phase 1 332348-12-6 10237
2
leucovorin Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 6006 143
3
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
4
Natalizumab Approved, Investigational Phase 4 189261-10-7
5 tannic acid Approved Phase 4,Not Applicable
6
Benzocaine Approved, Investigational Phase 4,Not Applicable 94-09-7, 1994-09-7 2337
7
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
8
Methotrexate Approved Phase 4,Phase 3,Phase 2 59-05-2, 1959-05-2 126941
9
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 62-33-9, 60-00-4 6049
10
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
11
rituximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 174722-31-7 10201696
12
Etanercept Approved, Investigational Phase 4 185243-69-0
13
Adalimumab Approved Phase 4 331731-18-1 16219006
14
Desflurane Approved Phase 4 57041-67-5 42113
15
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
16
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
17
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
18
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
19
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
20
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
21
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
22
Ritonavir Approved, Investigational Phase 4,Not Applicable 155213-67-5 392622
23
Efavirenz Approved, Investigational Phase 4,Not Applicable 154598-52-4 64139
24
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
25
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
26
Lopinavir Approved Phase 4 192725-17-0 92727
27
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-30-3 6037
29
BCG vaccine Investigational Phase 4,Phase 2
30
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
31 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
35 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Antacids Phase 4,Phase 3,Phase 2,Phase 1
38 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Central Nervous System Depressants Phase 4,Phase 1,Not Applicable
43 Antidotes Phase 4,Phase 3,Phase 2
44 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Vitamin B9 Phase 4,Phase 3,Phase 2,Not Applicable
46 Vitamin B Complex Phase 4,Phase 3,Phase 2,Not Applicable
47 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Folate Phase 4,Phase 3,Phase 2,Not Applicable
50 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 699)
# Name Status NCT ID Phase Drugs
1 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
2 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
3 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
4 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
5 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
6 Pertussis (Tdap) Vaccination in Pregnancy Unknown status NCT01698346 Phase 4
7 Inhibition of Co-Stimulation in Rheumatoid Arthritis Unknown status NCT02652273 Phase 4 Abatacept
8 Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td Completed NCT00601835 Phase 4
9 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine Completed NCT03552445 Phase 4
10 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
11 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
12 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
13 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
14 Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
15 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Completed NCT00347958 Phase 4
16 Study of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
17 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Completed NCT00457249 Phase 4
18 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
19 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
20 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® Completed NCT00319553 Phase 4
21 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
22 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
23 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
24 Post Marketing Surveillance for ADACEL™ in South Korea Completed NCT01137435 Phase 4
25 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
26 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
27 Tdap Vaccine in Post-Partum Women Completed NCT01711645 Phase 4
28 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
29 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
30 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
31 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
32 Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Completed NCT02783170 Phase 4
33 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
34 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
35 Interest of a Tetanus Test at a Fixed Remifentanil Concentration Before Laryngoscopy and Skin Incision Completed NCT02884310 Phase 4 Remifentanil adapted to SPI;Remifentanil fixed
36 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
37 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. Completed NCT00610168 Phase 4
38 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed NCT00777257 Phase 4
39 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
40 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
41 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
42 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
43 Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA) Completed NCT00111410 Phase 4 Anakinra (r-metHuIL-1ra)
44 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 Completed NCT00548171 Phase 4
45 Tropical Influenza Control Strategies for the Elderly Completed NCT02655874 Phase 4
46 Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients Completed NCT00287677 Phase 4 HAART
47 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
48 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
49 Evaluation of Boostrix™10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
50 Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents Completed NCT01362322 Phase 4

Search NIH Clinical Center for Tetanus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: tetanus

Sources

Genetic Tests for Tetanus

About this section
Sources

Anatomical Context for Tetanus

About this section

MalaCards organs/tissues related to Tetanus:

41
T Cells, Bone, Testes, Brain, Spinal Cord, B Cells, Heart
Sources

Publications for Tetanus

About this section

Articles related to Tetanus:

(show top 50) (show all 1924)
# Title Authors Year
1
Observational studies of non-specific effects of Diphtheria-Tetanus-Pertussis vaccines in low-income countries: Assessing the potential impact of study characteristics, bias and confounding through meta-regression. ( 30471957 )
2019
2
Intravascular Ketamine Increases Theta-Burst but Not High Frequency Tetanus Induced LTP at CA3-CA1 Synapses Within Three Hours and Devoid of an Increase in Spine Density. ( 29899695 )
2018
3
Immunization rates of pneumococcal, influenza and tetanus vaccines and knowledge and attitudes of adult patients who receive inpatient treatment at hospital: Point prevalence study. ( 29913102 )
2018
4
Myocarditis following diphtheria, whole-cell pertussis, and tetanus toxoid vaccination in a young infant. ( 29922028 )
2018
5
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults. ( 29172945 )
2018
6
Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. ( 29862604 )
2018
7
Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. ( 29254840 )
2018
8
Repeated vaccination with tetanus toxoid of plasma donors with pre-existing specific IgE transiently elevates tetanus-specific IgE but does not induce allergic symptoms. ( 29383792 )
2018
9
Effectiveness of Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination in the Prevention of Infant Pertussis in the U.S. ( 29910115 )
2018
10
Cyclic OmpC peptidic epitope conjugated to tetanus toxoid as a potential vaccine candidate against shigellosis. ( 29960802 )
2018
11
Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. ( 29438562 )
2018
12
A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital. ( 29217370 )
2018
13
Pharmacists' Attitudes and Practices Regarding Tetanus, Diphtheria and Pertussis (Tdap) Vaccination in Pregnancy and Surrounding Newborns. ( 29693570 )
2018
14
Tetanus toxin fragments and Bcl-2 fusion proteins: cytoprotection and retrograde axonal migration. ( 29890980 )
2018
15
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. ( 29066131 )
2018
16
The novel early use of dexmedetomidine in the management of tetanus. ( 29940468 )
2018
17
Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy: ERRATUM. ( 29652740 )
2018
18
Patient attitudes toward influenza and tetanus, diphtheria and acellular pertussis vaccination in pregnancy. ( 29907484 )
2018
19
A rare case of type 1 leprosy reactions following tetanus infection in a borderline tuberculoid leprosy patient and a literature review. ( 29908564 )
2018
20
Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. ( 29231748 )
2018
21
Immunization of preterms with hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: The position of the Italian Pediatric Society. ( 29880242 )
2018
22
Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study. ( 29960800 )
2018
23
Sero-efficacy of Vi-polysaccharide tetanus-toxoid typhoid conjugate vaccine (Typbar-TCV). ( 29351594 )
2018
24
Lichen planus following tetanus-diphtheria-acellular pertussis vaccination: A case report and review of the literature. ( 29326823 )
2018
25
Functional and proteomic comparison of different techniques to produce equine anti-tetanus immunoglobulin F(ab')2 fragments. ( 29883887 )
2018
26
Determinants and perceptions of the utilization of tetanus toxoid immunization among reproductive-age women in Dukem Town, Eastern Ethiopia: a community-based cross-sectional study. ( 29950171 )
2018
27
Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). ( 29702631 )
2018
28
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. ( 29336924 )
2018
29
A Pilot Study to Assess Safety and Feasibility of Intrathecal Immunoglobulin for the Treatment of Adults with Tetanus. ( 29916342 )
2018
30
Prognostic factors for generalized tetanus in adults: A retrospective study in a Chinese hospital. ( 29891121 )
2018
31
The role of timely initiation of antenatal care on protective dose tetanus toxoid immunization: the case of northern Ethiopia post natal mothers. ( 29907139 )
2018
32
Tetanus in a partially immunized child. ( 29866490 )
2018
33
Synthesis of peptide based epsilon toxin vaccine by covalent anchoring to tetanus toxoid. ( 29920342 )
2018
34
Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination and Autism Spectrum Disorder. ( 30104424 )
2018
35
Comparison of adverse events following pentavalent and diphtheria-tetanus-pertussis vaccines among Nigerian children. ( 28585776 )
2018
36
Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model. ( 28720318 )
2018
37
Potential Impact of Changes in the Schedule for Primary Diphtheria-Tetanus Toxoids-Pertussis Immunization as Control Strategy for Pertussis. ( 28859017 )
2018
38
Protection against Tetanus and Diphtheria in Europe: The impact of age, gender and country of origin based on data from the MARK-AGE Study. ( 29017961 )
2018
39
Immunity against measles, mumps, rubella, varicella, diphtheria, tetanus, polio, hepatitis A and hepatitis B among adult asylum seekers in the Netherlands, 2016. ( 29454516 )
2018
40
Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA. ( 29573876 )
2018
41
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. ( 29576304 )
2018
42
Evidence of Increase in Mortality After the Introduction of Diphtheria-Tetanus-Pertussis Vaccine to Children Aged 6-35 Months in Guinea-Bissau: A Time for Reflection? ( 29616207 )
2018
43
Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study. ( 29630439 )
2018
44
Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccines. ( 29866795 )
2018
45
A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response. ( 30010773 )
2018
46
A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children. ( 30047808 )
2018
47
A Pilot Study: Factors Influencing Compliance With Tetanus-Diphtheria Vaccine in Katsina State, Northwestern Nigeria. ( 30083576 )
2018
48
Adherence to pneumococcal conjugate vaccination schedule and uptake rate as compared to the established diphtheria-tetanus-acellular pertussis vaccination in Cyprus. ( 30115523 )
2018
49
Seroprevalence of Maternal and Cord Antibodies Specific for Diphtheria, Tetanus, Pertussis, Measles, Mumps and Rubella in Shunyi, Beijing. ( 30158679 )
2018
50
Factors that influenced the historical trends of tetanus and diphtheria. ( 30166043 )
2018
Sources

Variations for Tetanus

About this section
Sources

Expression for Tetanus

About this section
Search GEO for disease gene expression data for Tetanus.
Sources

Pathways for Tetanus

About this section

Pathways related to Tetanus according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.04 CD27 CD40LG CD79A IFNG IL10 IL13
2
ERK Signaling 64
Show member pathways
 13.87 CCR7 CD27 CD40LG IL10 IL13 IL2
3
PEDF Induced Signaling 64
Show member pathways
 13.72 CCR7 CD27 CD40LG IFNG IL10 IL13
4
TGF-Beta Pathway 64
Show member pathways
 13.55 IFNG IL10 IL13 IL2 IL2RA IL4
5
Akt Signaling 64
Show member pathways
 13.47 CCR7 CD27 CD40LG IL10 IL13 IL2
6
Cytokine Signaling in Immune system 66
Show member pathways
 13.36 CD27 CD40LG IFNG IL10 IL13 IL2
7
PAK Pathway 64
Show member pathways
 13.34 CCR7 CD27 CD40LG IL10 IL13 IL2
8
Allograft rejection 1 37
Show member pathways
 12.89 CD40LG IFNG IL10 IL13 IL2 IL2RA
9
Pathways in cancer 37
12.86 IFNG IL13 IL2 IL2RA IL4 IL5
10
Influenza A 37
Show member pathways
 12.81 IFNG IL13 IL2 IL2RA IL4 LTA
11
Immune response NFAT in immune response 22
Show member pathways
 12.72 CD40LG CD79A IFNG IL10 IL2 IL2RA
12
Th17 cell differentiation 37
Show member pathways
 12.67 IFNG IL10 IL13 IL2 IL2RA IL4
13
NF-kappaB Signaling 4
12.62 CD40LG CD79A IFNG IL10 IL2 IL2RA
14
T cell receptor signaling pathway 37
Show member pathways
 12.51 CD40LG IFNG IL10 IL2 IL4 IL5
15
Delta508-CFTR traffic / ER-to-Golgi in CF 22
Show member pathways
 12.47 NSF SNAP23 SNAP25 VAMP2 VAMP7
16
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.45 IFNG IL10 IL13 IL2 IL2RA IL4
17
Apoptosis Pathway 72
Show member pathways
 12.43 IL13 IL2 IL2RA IL5
18
IL-17 Family Signaling Pathways 65
Show member pathways
 12.33 IFNG IL13 IL4 IL5
19
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.27 IFNG IL10 IL13 IL2 IL2RA IL4
20
Toxoplasmosis 37
Show member pathways
 12.26 CD40LG IFNG IL10 IL4
21
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.19 IL10 IL13 SNAP25 VAMP2
22
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.16 IFNG IL10 IL13 IL2 IL2RA IL4
23
Th1 Differentiation Pathway 65
Show member pathways
 12.09 IFNG IL10 IL2 LTA
24
MAPK Pathway 72
Show member pathways
 12.06 IL13 IL2 IL2RA IL5
25
Synaptic vesicle cycle 37
Show member pathways
 12.02 NSF SNAP25 STX3 VAMP2
26
IL12-mediated signaling events 1
Show member pathways
 12.01 IFNG IL2 IL2RA IL4
27
Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics 61
Show member pathways
 11.96 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
28
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.92 CCR7 CD79A IFNG IL10 IL2 IL2RA
29
Jak-Stat Signaling Pathway (sino) 67
11.91 IFNG IL10 IL2 IL2RA
30
Glucocorticoid receptor regulatory network 1
11.9 IFNG IL13 IL2 IL4 IL5
31
Hematopoietic cell lineage 37
11.88 IL2RA IL4 IL5
32
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.8 IFNG IL10 IL13 IL2 IL4
33
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.77 IL2 IL2RA IL4 LTA
34
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.76 CD40LG IFNG IL2 IL2RA IL4 IL5
35
Dendritic Cells Developmental Lineage Pathway 65
11.75 IFNG IL10 IL2
36
IL4-mediated signaling events 1
11.72 CD40LG IL10 IL4 IL5 LTA
37
Lung fibrosis 1
11.67 IL13 IL4 IL5
38
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.67 CD40LG IFNG IL2
39
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.65 IFNG IL2 IL2RA
40
B Cell Development Pathways 65
11.59 CD27 CD40LG IL10
41
Interleukin-10 signaling 66
11.55 IL10 IL13 IL4
42
Malaria 37
11.55 CD40LG IFNG IL10
43
Innate Lymphoid Cell Differentiation Pathways 65
11.46 IFNG IL10 IL13 IL2 IL2RA IL4
44
Delta508-CFTR traffic / Sorting endosome formation in CF 22
Show member pathways
 11.44 NSF SNAP25 VAMP2
45
Development and heterogeneity of the ILC family 1
11.42 IFNG IL13 IL4 IL5
46
Inflammatory Response Pathway 1
11.36 CD40LG IFNG IL2 IL2RA IL4 IL5
47
Th2 Differentiation Pathway 65
11.36 IFNG IL10 IL13 IL2 IL2RA IL4
48
IL12 signaling mediated by STAT4 1
11.35 IFNG IL13 IL2 IL2RA
49
Cytokines and Inflammatory Response 1
11.26 IFNG IL10 IL13 IL2 IL4 IL5
50
G-protein signaling_RhoB regulation pathway 22
11.21 CD40LG IL10 IL13 IL2 IL4 IL5
Sources

GO Terms for Tetanus

About this section

Cellular components related to Tetanus according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.93 CCR7 CD27 CD40LG IL2RA VAMP3 VAMP7
2 synapse GO:0045202 9.88 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
3 phagocytic vesicle membrane GO:0030670 9.67 SNAP23 VAMP3 VAMP7
4 synaptic vesicle GO:0008021 9.67 SNAP25 STX3 VAMP2 VAMP7
5 clathrin-coated vesicle membrane GO:0030665 9.65 VAMP2 VAMP3 VAMP7
6 neuron projection GO:0043005 9.63 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
7 specific granule GO:0042581 9.56 SNAP23 STX3
8 secretory granule GO:0030141 9.56 STX3 VAMP2 VAMP3 VAMP7
9 azurophil granule GO:0042582 9.54 SNAP23 STX3
10 zymogen granule membrane GO:0042589 9.52 STX3 VAMP2
11 synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex GO:0070032 9.43 SNAP25 VAMP2
12 external side of plasma membrane GO:0009897 9.43 CCR7 CD27 CD40LG CD79A IL13 IL2RA
13 SNARE complex GO:0031201 9.1 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
14 plasma membrane GO:0005886 10.17 CCR7 CD27 CD40LG CD79A IL2RA LTA
15 extracellular region GO:0005576 10.16 CD27 CD40LG IFNG IL10 IL13 IL2
16 extracellular space GO:0005615 10.15 CD40LG IFNG IL10 IL13 IL2 IL4

Biological processes related to Tetanus according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.98 CD27 CD79A IFNG IL2RA
2 vesicle-mediated transport GO:0016192 9.98 NSF STX3 VAMP2 VAMP3 VAMP7
3 response to lipopolysaccharide GO:0032496 9.95 CCR7 IL10 IL13 LTA
4 negative regulation of inflammatory response GO:0050728 9.87 IL10 IL2 IL2RA
5 B cell differentiation GO:0030183 9.86 CD40LG CD79A IL10 IL4
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.85 CD27 CD40LG LTA
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 IFNG IL13 IL2 IL4
8 positive regulation of T cell proliferation GO:0042102 9.83 CD40LG IL2 IL2RA IL4
9 cytokine-mediated signaling pathway GO:0019221 9.8 IL10 IL13 IL2 IL2RA IL4 IL5
10 negative regulation of endothelial cell apoptotic process GO:2000352 9.79 IL10 IL13 IL4
11 long-term synaptic potentiation GO:0060291 9.78 MPP2 SNAP25 STX3 VAMP2
12 B cell proliferation GO:0042100 9.77 CD40LG CD79A IL10
13 positive regulation of B cell proliferation GO:0030890 9.76 IL13 IL2 IL4 IL5
14 regulation of signaling receptor activity GO:0010469 9.76 CD40LG IFNG IL10 IL13 IL2 IL4
15 calcium ion regulated exocytosis GO:0017156 9.75 VAMP2 VAMP3 VAMP7
16 positive regulation of interleukin-12 production GO:0032735 9.74 CCR7 CD40LG IFNG
17 membrane fusion GO:0061025 9.73 SNAP23 STX3 VAMP2 VAMP3
18 regulation of regulatory T cell differentiation GO:0045589 9.72 IFNG IL2 IL2RA
19 vesicle fusion GO:0006906 9.71 SNAP23 SNAP25 STX3 VAMP7
20 negative regulation of growth of symbiont in host GO:0044130 9.69 IL10 LTA
21 positive regulation of receptor recycling GO:0001921 9.69 NSF VAMP3
22 synaptic vesicle fusion to presynaptic active zone membrane GO:0031629 9.69 SNAP23 SNAP25 STX3
23 synaptic vesicle priming GO:0016082 9.68 SNAP23 SNAP25
24 interleukin-2-mediated signaling pathway GO:0038110 9.68 IL2 IL2RA
25 synaptic vesicle docking GO:0016081 9.68 SNAP25 STX3
26 positive regulation of isotype switching to IgG isotypes GO:0048304 9.67 IL2 IL4
27 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL10 IL4
28 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL2 IL5 VAMP3
29 Golgi to plasma membrane protein transport GO:0043001 9.67 NSF VAMP2 VAMP3 VAMP7
30 SNARE complex assembly GO:0035493 9.66 VAMP3 VAMP7
31 natural killer cell degranulation GO:0043320 9.66 VAMP2 VAMP7
32 negative regulation of lymphocyte proliferation GO:0050672 9.65 IL2 IL2RA
33 exocytic insertion of neurotransmitter receptor to postsynaptic membrane GO:0098967 9.64 SNAP25 STX3
34 eosinophil degranulation GO:0043308 9.64 VAMP2 VAMP7
35 mucus secretion GO:0070254 9.63 VAMP2 VAMP3
36 regulation of isotype switching GO:0045191 9.63 IL10 IL4
37 type 2 immune response GO:0042092 9.62 IL10 IL4
38 positive regulation of T cell differentiation GO:0045582 9.62 CD27 IL2 IL2RA IL4
39 negative regulation of complement-dependent cytotoxicity GO:1903660 9.61 IL13 IL4
40 regulation of histamine secretion by mast cell GO:1903593 9.61 VAMP2 VAMP3
41 regulation of T cell homeostatic proliferation GO:0046013 9.6 IL2 IL2RA
42 exocytosis GO:0006887 9.5 NSF SNAP23 SNAP25 STX3 VAMP2 VAMP3
43 immune response GO:0006955 9.32 CCR7 CD40LG IFNG IL10 IL13 IL2
44 negative regulation of apoptotic process GO:0043066 10.09 CD27 CD40LG IL10 IL2 IL4
45 inflammatory response GO:0006954 10.05 CCR7 CD40LG IL10 IL13 IL5

Molecular functions related to Tetanus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.71 IL10 IL2 IL4 IL5
2 SNARE binding GO:0000149 9.62 NSF STX3 VAMP2 VAMP7
3 SNAP receptor activity GO:0005484 9.56 SNAP23 SNAP25 STX3 VAMP7
4 syntaxin-1 binding GO:0017075 9.46 NSF SNAP25 VAMP2 VAMP3
5 syntaxin binding GO:0019905 9.35 NSF SNAP23 SNAP25 VAMP2 VAMP7
6 cytokine activity GO:0005125 9.23 CD40LG IFNG IL10 IL13 IL2 IL4
7 protein binding GO:0005515 10.32 CD27 CD40LG CD79A IFNG IL10 IL13
Sources

Sources for Tetanus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....